An interventional study of Screenig Phase in Oncologic Diseases, sponsored by University of Salamanca. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by University of Salamanca · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies in Sarcopenia with a site in Spain — 33 open to participants now, 40 under way, none of them phase 3. Sarcopenia · Spain.
Among the 99 studies in Sarcopenia with a site in Spain, this one is the 60th largest by planned enrollment of the 77 interventional ones that give a count, is one of 16 that started in 2026, is one of 70 with no phase, reaches primary completion later than 19 of the 39 other live ones, and was the 83rd registered.
1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.
Browse Sarcopenia studies →33 of the 99 studies in Sarcopenia with a site in Spain are open now. Recruiting first, the newest first:
University of Valencia · Sites in Spain
Ages 18–99
Universidad de Granada · Sites in Spain
Ages 65+
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · Sites in Spain
Ages 80+
Sara Casanova Prieto · Sites in Spain
Ages 18+
University of Salamanca · Sites in Spain
Ages 40+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 16 started in 2026.
This study's planned enrollment of 40 is below the median of 60 across 860 interventional studies indexed under Sarcopenia.
Median enrollment 72 across the 77 interventional studies, 156 across the 22 observational. Of the 48 that completed or were terminated, 2 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 99 have an industry lead sponsor. The 10 most frequent:
University of Salamanca is the lead sponsor of 112 studies on the registry; 47 are open to participants now.
University of Salamanca has 7 studies filed under Sarcopenia — fewer than ten, so there is no comparison to draw.
15 of the studies in Sarcopenia with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07387770University of SalamancaMuscle Deterioration in Hospitalized Cancer Patient | 2026-11-30 |
| NCT07275996Universidad de BurgosNeuromuscular and Multi-Omics Synergy of Combined Creatine × HMB Supplementation Plus Exercise to Improve Muscle Function in Sarcopenic Frailty | 2026-12-30 |
| NCT06634316Maimónides Biomedical Research Institute of CórdobaSarcopenia in Patients With Heart Failure | 2026-12-31 |
| NCT07447375University of SalamancaExercise During Hemodialysis: Impact on Sarcopenia and Sleep Quality | 2026-12-31 |
| NCT06015971Maimónides Biomedical Research Institute of CórdobaOmega-3 Fatty Acids and Nutritional Support in Gastrointestinal Cancer | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 99 studies in Sarcopenia with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cancer cachexia and skeletal muscle deterioration represent significant challenges in oncology, affecting up to 42% of cancer patients and correlating with poor clinical outcomes, increased treatment toxicity, and reduced overall survival. Early identification of patients at risk through comprehensive musculoskeletal assessment is essential for timely therapeutic intervention.
This paper presents a detailed protocol for the longitudinal evaluation of skeletal muscle deterioration in hospitalized cancer patients using an integrated, multimodal approach. The protocol combines validated questionnaires (SARC-F, MSAS, EORTC QLQ-C30, and PSQI), functional measurements (handgrip strength), body composition analysis (bioelectrical impedance analysis), neuromuscular assessment (surface electromyography), and serum biomarkers (basic panel approach).
The study aims to recruit 45-50 patients with confirmed malignancy requiring hospitalization for ≥4 days, with daily functional measurements and biomarker evaluations at admission and discharge. The protocol prioritizes methodological rigor in vulnerable populations, incorporates standardized procedures for real-world clinical settings, and emphasizes quality control measures.
Expected outcomes include the identification of longitudinal patterns of muscle deterioration, validation of serum biomarker signatures for cachexia detection, and characterization of neuromuscular fatigue patterns using surface electromyography. This comprehensive framework addresses current gaps in skeletal muscle assessment during acute hospitalization and provides a foundation for future interventional studies. The protocol adheres to international ethical standards and considerations for research in vulnerable populations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
EMG screening
Diagnostic Test: Screenig Phase
EMG Parameters Analyzed: * Amplitude: Root mean square (RMS) during maximal voluntary contraction (MVC) and during sustained contraction, normalized to %MVC. * Frequency: Median frequency (MDF) and mean frequency (MNF) calculated using the fast Fourier transform (FFT) with 0.5-1 s sliding windows. Fatigue Indices * Rate of MDF decline (Hz/s) during sustained contraction. * Ratio of RMS at the end versus the beginning of the sustained contraction. * Time to task failure (s) during sustained effort. Quality Control: Quality control included real-time visual inspection of signals for movement artifacts, verification of baseline stability (resting activity \<10-20 µV RMS), and complete post-acquisition review with exclusion of segments containing \>20% artifact contamination.
SARC-F Sarcopenia Screening Tool
The SARC-F questionnaire (Strength, Assistance with walking, Rising from a chair, Climbing stairs, and Falls) will be administered to all participants at baseline and at discharge. This five-item instrument evaluates functional limitations, with total scores ranging from 0 to 10; scores ≥4 indicate an increased risk of sarcopenia. The SARC-F demonstrates a sensitivity of 71-89% and a specificity of 84-91% for sarcopenia detection across diverse populations.
Time frame: Baseline and up to 10 days
Symptoms prevalence. Memorial Symptom Assessment Scale (MSAS)
The Memorial Symptom Assessment Scale (MSAS) will be administered using the validated Spanish version by Llamas-Ramos et al. The 24-item short form (MSAS-SF) assesses symptom frequency, severity, and associated distress across three core dimensions: the Global Distress Index, the Physical Symptom Subscale, and the Psychological Symptom Subscale. The instrument has demonstrated excellent psychometric properties in Spanish-speaking cancer populations (Cronbach's α \> 0.80) and superior sensitivity to symptom changes compared with single-item scales.
Time frame: Baseline and and up to 10 days
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
The EORTC QLQ-C30 is the gold-standard instrument for assessing quality of life in cancer patients. This 30-item questionnaire evaluates five functional scales (physical, role, emotional, cognitive, and social functioning), global health status/quality of life, symptom scales (fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, and diarrhea), and financial difficulties. Scores are linearly transformed to 0-100 scales, with higher scores indicating better functioning on functional scales and greater symptom burden on symptom scales. The EORTC QLQ-C30 has demonstrated prognostic validity for survival outcomes across multiple cancer types.
Time frame: Baseline and and up to 10 days
Pittsburgh Sleep Quality Index (PSQI)
The Pittsburgh Sleep Quality Index (PSQI) evaluates sleep quality over the preceding month using 19 self-reported items, yielding seven component scores (subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction). The global PSQI score ranges from 0 to 21, with scores \>5 indicating poor sleep quality. Among cancer patients, the PSQI demonstrates 89.6% sensitivity and adequate psychometric properties for detecting sleep disturbances.
Time frame: Baseline and up to 10 days
Bioimpedance Electrical Analysis
Bioelectrical Impedance Analysis (BIA) will be performed using InBody equipment (bipedal configuration, 50 kHz impedance measurement). Standardized protocols will include: (1) 4-6 h of fasting, when feasible; (2) micturition 30 min prior to assessment; (3) a 15-min supine rest period to allow for fluid redistribution; and (4) documentation of hydration status using a structured clinical scale.
Time frame: Baseline and and up to 10 days
Handgrip Strength Assessment
Handgrip strength will be measured daily using a calibrated digital dynamometer (EH101, China), following the American Society of Hand Therapists (ASHT) protocol. Prior to study initiation, the dynamometer underwent precision testing using calibrated weights (error \<5%) and reliability assessment in 12 healthy volunteers (ICC = 0.92, 95% CI: 0.86-0.96).
Time frame: Baseline and through study completion, an average of 10 days
Surface Electromyography Assessment
Surface electromyography (sEMG) will be acquired using the mDurance system (Shimmer3 wireless hardware), with a sampling rate of 1000 Hz, band-pass filtering from 10 to 500 Hz, and a 50 Hz notch filter to eliminate power-line interference. Electrode Preparation and Placement Skin will be prepared by shaving with disposable razors, gentle abrasion with fine-grit sandpaper, and cleansing with 70% alcohol, followed by complete air-drying. Disposable Ag/AgCl electrodes (20 mm interelectrode distance, in accordance with SENIAM recommendations) will be placed using precise anatomical landmarks on the vastus lateralis, vastus medialis, and upper trapezius muscles.
Time frame: Baseline and through study completion, an average of 10 days
Blood sample collection
Blood samples will be collected during routine morning laboratory draws at admission and discharge, with additional volumes (10-15 mL) obtained for research purposes. Serum will be separated via centrifugation at 3000 rpm for 10 minutes and stored at -80°C until batch analysis. All analytical procedures will be performed in accordance with standard hospital clinical laboratory protocols.
Time frame: Baseline and up to 10 days
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Nov 2026, 4 months after the start.
Of 497 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 4 months is below that.
Counting every sponsor, half of 509 studies reached it within 18 months; a quarter within 8 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.